CSU.TO 67.76NFLX 0.62LLY 6.15EVR -7.36MSFT -11.38DAL -0.09JPM 1.48
Daily Stock Opinions and Ratings
The ultimate 360° Tracker Your financial life in one place, automatically
Stockchase Opinions

Jonathen Wellum, B. Comm, B. ScLabopharm IncDDS.TODON'T BUYMar 15, 2002

Speculative and risky. In a competitive sector.
Jonathen Wellum, B. Comm, B. ScJonathen Wellum, B. Comm, B. Sc
Unknown
Unlock Rating
$5.38

Stock price when the opinion was issued

biotechnologypharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
Get Signals Create your Watchlist

You might be interested:

HOLD

Labopharm Inc(DDS.TO)

Jan 08, 2009
Broke through the 200-day moving average at about $1.50. Looks like the momentum may start to peter out but there is some pretty good support around $1.40. If her broke that, you should Sell.
Photo of Hap (Robert) Sneddon FCSIHap (Robert) Sneddon FCSIUnlock Rating
$1.83

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Labopharm Inc(DDS.TO)

Dec 14, 2007
Has disappointed everyone for a long time. Didn't get approval on their product. Stock has been decimated. Thinks the worst is over, but it will be a long recovery. He was actually Short the stock for a while. If you own, Hold and see what they do, but don't be a buyer.
Photo of Peter HodsonPeter Hodson
No
Unlock Rating
$1.07

Stock price when the opinion was issued

biotechnologypharmaceutical
SELL

Labopharm Inc(DDS.TO)

Nov 15, 2007
Has been a major disappointment. Guided that approvals would be fairly easy to receive, which didn't happen. Trials have been okay, not all that inclusive, so there is a lot of uncertainty.
Photo of Lesley MarksLesley Marks
No
Unlock Rating
$1.23

Stock price when the opinion was issued

biotechnologypharmaceutical
BUY

Labopharm Inc(DDS.TO)

Nov 06, 2006
Has been doing fairly well recently because they had their European and Canadian approval for their painkiller. Once they get the US of the way, it should be back over the $7 mark.
Photo of Chyanne FickesChyanne FickesUnlock Rating
$5.56

Stock price when the opinion was issued

biotechnologypharmaceutical
BUY

Labopharm Inc(DDS.TO)

Oct 02, 2006
It is a small stock. Believes it will be a winner.
Photo of Chyanne FickesChyanne Fickes
No
Unlock Rating
$5.83

Stock price when the opinion was issued

biotechnologypharmaceutical
WATCH

Labopharm Inc(DDS.TO)

Aug 23, 2005
Entering into a licensing/distribution agreement with Purdue Pharma in the US. Did a disatrous financing last year and the stock sold off. This deal was a rabbit pulled out of a hat. The stock will probably flatline for a bit after this deal. Best to see quarter after quarter how revenues kick in.
Photo of Peter HodsonPeter Hodson
No
Unlock Rating
$4.89

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Labopharm Inc(DDS.TO)

Jan 17, 2005
Received approval in France for its drug tramadol. Has stubbed its toes many times with investors. Large outstanding stock holding (40 Million?) could come out and flood the market.
Photo of Andrew McCreathAndrew McCreath
No
Unlock Rating
$4.17

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Labopharm Inc(DDS.TO)

Jan 17, 2005
Drug companies in general scare value investors. Drugs they produce might injure or kill people. Also there's a history of companies suing each other because of infringement on property rights which can tie up a small company like this. Although they got French approval, FDA could be a whole different matter.
Photo of David BaskinDavid Baskin
No
Unlock Rating
$4.17

Stock price when the opinion was issued

biotechnologypharmaceutical
WATCH

Labopharm Inc(DDS.TO)

Aug 26, 2004
Management is at its risk. If they start in Europe, the stock will improve. Therefore, be cautious.
Photo of Glenn Paradis, BA, CFAGlenn Paradis, BA, CFAUnlock Rating
$4.03

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Labopharm Inc(DDS.TO)

May 17, 2004
Did an issue and it was a disaster. Hasn't even come close to where the issue was priced at. Behind schedule as compared to their competitors.
Photo of Peter HodsonPeter Hodson
No
Unlock Rating
$4.09

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Labopharm Inc(DDS.TO)

May 29, 2003
Still suffering from a plethora of disappointments from late 2001 and 2002. Will have a challenge moving up from where it is. Prefers others.
Photo of Andrew McCreathAndrew McCreathUnlock Rating
$5.18

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Labopharm Inc(DDS.TO)

May 17, 2002
Volatile. Too few projects on the go. Risky.
Photo of Bruce CooperBruce CooperUnlock Rating
$5.34

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Labopharm Inc(DDS.TO)

May 02, 2002
Interesting technology. Future is unclear. Risky.
Photo of Bruce CooperBruce CooperUnlock Rating
$4.75

Stock price when the opinion was issued

biotechnologypharmaceutical
PAST TOP PICK

Labopharm Inc(DDS.TO)

Apr 01, 2002
(Was a top pick on Dec 18 down 46%) Still likes. Got hit with the pull out of Aventis, but should be able to get new deals over the next 6 months. Don't buy until they do strike a deal.
Photo of Glenn Paradis, BA, CFAGlenn Paradis, BA, CFAUnlock Rating
$5.80

Stock price when the opinion was issued

biotechnologypharmaceutical

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

AEM.TO -17.72$228.02
COST -0.48$971.87
JPM 1.48$312.37
TOU.TO -1.69$63.73
SHOP.TO -8.75$152.79

Today's Top Picks

CSU.TO 67.76$2969.32
NFLX 0.62$82.18
LLY 6.15$1131.42
EVR -7.36$339.43
MSFT -11.38$416.67

Popular Articles

Latest Sell Signals

GSY.TO 0.43$40.53
CSCO -8.36$121.64
LULU -10.69$114.23
SES.TO -0.19$21.33
GFL.TO -0.26$49.51

Most Recent Experts

Brian Madden

Brian Madden

First Avenue Investment Counsel

The Panic-Proof Portfolio (Stockchase Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Darren Sissons

Darren Sissons

Campbell Lee & Ross

The Weekly Buzzing Stocks by Billy Kawasaki

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

Joe Terranova

Joe Terranova

Virtus Investment Partners

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica